[go: up one dir, main page]

WO2009053754A3 - Novel crystalline forms - Google Patents

Novel crystalline forms Download PDF

Info

Publication number
WO2009053754A3
WO2009053754A3 PCT/GB2008/050992 GB2008050992W WO2009053754A3 WO 2009053754 A3 WO2009053754 A3 WO 2009053754A3 GB 2008050992 W GB2008050992 W GB 2008050992W WO 2009053754 A3 WO2009053754 A3 WO 2009053754A3
Authority
WO
WIPO (PCT)
Prior art keywords
crystalline forms
novel crystalline
novel
relates
tegaserod
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2008/050992
Other languages
French (fr)
Other versions
WO2009053754A2 (en
Inventor
Abhay Gaitonde
Bindu Manojkumar
Rahul Bhalerao
Sinderpal Tank
Vikas Padalkar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Generics UK Ltd
Mylan Pharmaceuticals Pvt Ltd
Original Assignee
Generics UK Ltd
Mylan Development Centre Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Generics UK Ltd, Mylan Development Centre Pvt Ltd filed Critical Generics UK Ltd
Publication of WO2009053754A2 publication Critical patent/WO2009053754A2/en
Publication of WO2009053754A3 publication Critical patent/WO2009053754A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to novel crystalline forms of the citrate salt of tegaserod, and to processes for the preparation of these novel crystalline forms. The invention also relates to pharmaceutical compositions containing these novel polymorphs, and to uses of said compositions to provide methods of treating patients suffering from gastrointestinal disorders.
PCT/GB2008/050992 2007-10-24 2008-10-24 Novel crystalline forms Ceased WO2009053754A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2109/MUM/2007 2007-10-24
IN2109MU2007 2007-10-24

Publications (2)

Publication Number Publication Date
WO2009053754A2 WO2009053754A2 (en) 2009-04-30
WO2009053754A3 true WO2009053754A3 (en) 2009-09-03

Family

ID=40289317

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2008/050992 Ceased WO2009053754A2 (en) 2007-10-24 2008-10-24 Novel crystalline forms

Country Status (1)

Country Link
WO (1) WO2009053754A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006116953A1 (en) * 2005-05-02 2006-11-09 Zentiva, A.S. A method for the preparation of tegaserod and slected salts thereof
EP1939176A1 (en) * 2006-12-22 2008-07-02 Novartis AG Salts of Tegaserod

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0297651B1 (en) 1987-06-29 1993-11-03 Duphar International Research B.V Anellated indole derivatives
HUT64023A (en) 1991-03-22 1993-11-29 Sandoz Ag Process for producing aminoguanidine derivatives and pharmaceutical compositions comprising such compounds
GB9721139D0 (en) 1997-10-07 1997-12-03 Glaxo Group Ltd Medicaments

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006116953A1 (en) * 2005-05-02 2006-11-09 Zentiva, A.S. A method for the preparation of tegaserod and slected salts thereof
EP1939176A1 (en) * 2006-12-22 2008-07-02 Novartis AG Salts of Tegaserod

Also Published As

Publication number Publication date
WO2009053754A2 (en) 2009-04-30

Similar Documents

Publication Publication Date Title
WO2009064460A3 (en) Gastrointestinal delivery systems
WO2008001195A3 (en) Novel processes for the preparation of dpp iv inhibitors
WO2008132139A3 (en) New heterocyclic derivatives useful for the treatment of cns disorders
WO2009111700A3 (en) Oxadiazoanthracene compounds for the treatment of diabetes
WO2009067686A3 (en) Sunitinib hemi-l-malate, polymorphs and preparation thereof, polymorphs of racemic sunitinib malate, compositins containing sunitinib base and malic acid and preparation thereof
WO2010011772A3 (en) Tri-cyclic pyrazolopyridine kinase inhibitors
TW200612892A (en) Novel compounds
WO2008152099A3 (en) Aryl/hetarylamides as modulators of the ep2 receptor
WO2008094992A3 (en) 2-aminopyridine derivatives useful as kinase inhibitors
WO2009104021A3 (en) Novel polymorphs and processes for their preparation
WO2007068894A3 (en) Substituted diphenylethers, -amines, -sulfides and -methanes for the treatment of respiratory disease
WO2007138282A3 (en) Bi-aryl or aryl-heteroaryl substituted indoles
WO2010055082A3 (en) New crystal form of sunitinib malate
TW200745003A (en) Novel compounds
TW200630336A (en) Novel compounds
WO2007052023A3 (en) Novel compounds
WO2011023367A3 (en) Bisphosphonate-prodrugs
UA96447C2 (en) Polymorph forms of (2s)-(4e)-n-methyl-5- (3-isopropoxypyridin) yl]-4-penten-2-amine for the treatment of central nervous system disorders
WO2005086656A3 (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
WO2010049449A3 (en) Novel salts of sunitinib
WO2008088779A3 (en) Solid state forms of 5-azacytidine and processes for preparation thereof
WO2008129501A3 (en) Pharmaceutical compositions of duloxetine
WO2010006904A3 (en) Crystalline forms of rabeprazole sodium
WO2008081268A3 (en) Pharmaceutical compositions of entacapone
WO2008033935A3 (en) Vinorelbine derivatives

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08806799

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08806799

Country of ref document: EP

Kind code of ref document: A2